Live price temporarily unavailable.
Galectin Therapeutics (GALT) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$21.5M | −$16.2M | −$13.6M | −$13.4M | −$23.4M | −$30.2M | −$38.4M | −$38.1M | −$42.4M | −$20.1M |
| Net income | −$21.4M | −$16.2M | −$13.9M | −$13.3M | −$23.5M | −$30.5M | −$38.8M | −$41.1M | −$47.0M | −$30.8M |
| EPS (diluted) | −$0.76 | −$0.49 | −$0.38 | −$0.39 | −$0.41 | −$0.52 | −$0.65 | −$0.74 | −$0.76 | −$0.48 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.4M | $3.05M | $8.25M | $47.5M | $27.1M | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M |
| Total assets | $15.8M | $4.16M | $9.01M | $48.5M | $29.6M | $41.8M | $21.3M | $28.2M | $17.5M | $19.5M |
| Total liabilities | $3.78M | $2.97M | $2.11M | $2.87M | $5.41M | $39.2M | $53.5M | $88.4M | $120.6M | $145.7M |
| Shareholders' equity | $10.3M | −$530.0K | $5.17M | $43.9M | $22.5M | $893.0K | −$33.9M | −$62.0M | −$104.8M | −$127.9M |
| Cash flow | ||||||||||
| Operating cash flow | −$16.4M | −$15.9M | −$10.2M | −$10.8M | −$20.6M | −$24.3M | −$31.1M | −$33.0M | −$41.8M | −$23.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$9.07M | −$12.4M | −$7.90M | −$4.63M | −$4.20M | −$3.37M | −$4.08M | −$3.98M |
| Net income | −$11.2M | −$12.0M | −$9.63M | −$7.52M | −$8.18M | −$5.50M | −$5.05M | −$9.11M |
| EPS (diluted) | −$0.18 | −$0.19 | −$0.15 | −$0.12 | −$0.13 | −$0.08 | −$0.08 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $27.1M | $15.1M | $7.43M | $13.8M | $11.5M | $17.7M | $14.1M | $13.3M |
| Total assets | $29.0M | $17.5M | $9.53M | $15.6M | $12.9M | $19.5M | $15.8M | $14.8M |
| Total liabilities | $121.5M | $120.6M | $121.8M | $132.8M | $136.4M | $145.7M | $146.0M | $151.7M |
| Shareholders' equity | −$94.2M | −$104.8M | −$114.0M | −$118.9M | −$125.3M | −$127.9M | −$132.0M | −$138.6M |
| Cash flow | ||||||||
| Operating cash flow | −$8.54M | −$12.8M | −$7.69M | −$6.60M | −$3.54M | −$6.04M | −$3.87M | −$2.44M |
From Galectin Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Galectin Therapeutics in our feed yet.